$118 Million is the total value of Knoll Capital Management, LLC's 19 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 46.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ABEO | Abeona Therapeutics Inc | $37,756,000 | +11.5% | 2,359,767 | 0.0% | 32.08% | -7.7% | |
| BHVN | Biohaven Pharmactl Hldg Co L | $29,633,000 | +53.4% | 749,815 | 0.0% | 25.18% | +27.0% | |
| CRBP | Buy | Corbus Pharmaceuticals HLDGS | $19,765,000 | -16.0% | 3,913,874 | +1.5% | 16.80% | -30.5% |
| ECOR | New | Electrocore Inc | $6,551,000 | – | 396,825 | +100.0% | 5.57% | – |
| AMPE | Ampio Pharmaceuticals Inc. | $5,710,000 | -35.3% | 2,595,484 | 0.0% | 4.85% | -46.5% | |
| KRYS | Krystal Biotech Inc | $4,461,000 | +47.4% | 300,000 | 0.0% | 3.79% | +22.0% | |
| ENTX | New | Entera Bio Ltd | $2,996,000 | – | 475,540 | +100.0% | 2.55% | – |
| GLMD | New | Galmed Pharmaceuticals Ltd | $2,499,000 | – | 210,000 | +100.0% | 2.12% | – |
| VBLT | Vascular Biogenics LTD | $1,973,000 | -4.4% | 896,771 | 0.0% | 1.68% | -20.8% | |
| AVXL | Anavex Life Sciences Corp | $1,897,000 | -5.1% | 724,205 | 0.0% | 1.61% | -21.5% | |
| ALDX | Aldeyra Therapeutics Inc | $987,000 | +6.0% | 124,096 | 0.0% | 0.84% | -12.2% | |
| EIGR | Eiger Biopharmaceuticals Inc | $918,000 | +23.9% | 75,238 | 0.0% | 0.78% | +2.5% | |
| SNGX | Soligenix Inc. | $813,000 | -50.4% | 837,800 | 0.0% | 0.69% | -58.9% | |
| VNRX | Volition RX LTD | $703,000 | -16.7% | 351,538 | 0.0% | 0.60% | -31.1% | |
| EVOK | Evoke Pharma Inc | $688,000 | +20.3% | 275,000 | 0.0% | 0.58% | -0.3% | |
| CDXC | New | Chromadex Corp | $178,000 | – | 47,866 | +100.0% | 0.15% | – |
| LPCN | New | Lipocine Inc New | $65,000 | – | 50,000 | +100.0% | 0.06% | – |
| CATS | New | Catasys Inc | $61,000 | – | 9,081 | +100.0% | 0.05% | – |
| ADXSW | Advaxis Inc.w exp 07/15/201 | $20,000 | -55.6% | 112,500 | 0.0% | 0.02% | -63.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Aldeyra Therapeutics Inc | 35 | Q3 2023 | 31.6% |
| Corbus Pharmaceuticals HLDGS | 30 | Q3 2022 | 46.5% |
| Abeona Therapeutics Inc | 30 | Q3 2022 | 34.8% |
| Biohaven Pharmactl Hldg Co L | 26 | Q3 2023 | 79.6% |
| Entera Bio Ltd | 22 | Q3 2023 | 7.8% |
| Ampio Pharmaceuticals Inc. | 21 | Q2 2018 | 11.0% |
| Soligenix Inc. | 20 | Q3 2022 | 1.7% |
| Eiger Biopharmaceuticals Inc | 19 | Q3 2022 | 5.8% |
| Applied Therapeutics Inc | 18 | Q3 2023 | 19.7% |
| Alcobra Ltd | 18 | Q3 2017 | 6.5% |
View Knoll Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| HOOKIPA Pharma Inc. | June 20, 2023 | 5,517,385 | 6.8% |
| Applied Therapeutics Inc. | January 23, 2023 | 3,450,000 | 7.2% |
| Orgenesis Inc. | August 14, 2020 | 1,316,364 | 5.9% |
| Corbus Pharmaceuticals Holdings, Inc. | February 14, 2020 | 5,045,870 | 7.1% |
| ABEONA THERAPEUTICS INC. | February 14, 2018 | 2,359,767 | 5.0% |
| SOLIGENIX, INC. | November 13, 2017 | 870,000 | 9.9% |
| ABEONA THERAPEUTICS INC. | February 14, 2017 | 2,359,767 | 5.9% |
| ALCOBRA LTD. | February 14, 2017 | 1,205,498 | 4.4% |
| Ampio Pharmaceuticals, Inc. | February 14, 2017 | 2,738,322 | 4.8% |
| RITTER PHARMACEUTICALS INC | February 14, 2017 | 952,434 | 8.2% |
View Knoll Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-01-16 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-04 |
| 13F-HR | 2023-08-15 |
| SC 13G | 2023-06-20 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G | 2023-01-23 |
| 13F-HR | 2022-11-14 |
View Knoll Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.